GSK plc announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupuserythematosus (SLE) and lupus nephritis (LN). GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus.
This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus; Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US.
Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria.
